MPS Limited has acquired Unbound Medicine, Inc. to enhance its position in the healthcare knowledge management sector by integrating Unbound's AI-driven platform with MPS's global technology infrastructure, thereby expanding their market reach and improving access to evidence-based healthcare solutions.
Information on the target
Unbound Medicine, Inc. is a pioneering company that has spent over 25 years at the forefront of medical knowledge, information science, and artificial intelligence (AI). The organization specializes in transforming complex medical content into accessible and actionable knowledge, which is delivered to clinicians and students precisely when they need it. Unbound Medicine's clientele includes medical schools, nursing programs, hospital systems, and professional societies across North America, all served through a subscription-based institutional model.
The company’s AI-powered clinical decision-support and healthcare education platform is designed to enhance the learning experience and improve patient care by providing instant access to the best available evidence. This innovative approach has established Unbound Medicine as a trusted resource in the healthcare sector, ensuring that healthcare professionals can make informed decisions at the point of care.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry overview in the target’s specific country
The healthcare knowledge management industry in the United States is experiencing significant growth, driven by the increasing demand for evidence-based healthcare solutions and the integration of advanced technologies suc
Similar Deals
Vanderbilt University → California College of the Arts
2027
NIIT Learning Systems Limited → SweetRush, Inc.
2026
Country Roads Angel Network (CRAN) → Brite
2025
Cadence Education → My Special Spot
2025
MPS Limited
invested in
Unbound Medicine
in 2026
in a Other deal